SCHEMBL1014078

SCHEMBL1014078

Cc1nc(N(C)C)ncc1C(=O)NC1CCCC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 5/20 0.56
LMNA P02545 2/20 0.49
NR3C1 P04150 3/20 0.48
ALDH1A1 P00352 4/20 0.47
KDM4E B2RXH2 2/20 0.47
POLB P06746 1/20 0.47
RAB9A P51151 2/20 0.46
NPC1 O15118 2/20 0.46
CYP1A2 P05177 2/20 0.45
CYP2C19 P33261 2/20 0.45
TSHR P16473 1/20 0.45
HSD17B10 Q99714 1/20 0.45
GLA P06280 1/20 0.44
MAPK1 P28482 1/20 0.44
FLT3 P36888 2/20 0.43
TYRO3 Q06418 2/20 0.43
MERTK Q12866 2/20 0.43
GAS6 Q14393 2/20 0.43
SPR P35270 2/20 0.43
MAPT P10636 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1017688 0.99 HPGD (0.55) HPGDLMNANR3C1ALDH1A1KDM4E
SCHEMBL1018675 0.99 HPGD (0.55) HPGDLMNANR3C1ALDH1A1KDM4E
SCHEMBL1013682 0.83 LMNA (0.54) HPGDLMNANR3C1ALDH1A1KDM4E
SCHEMBL1016181 0.82 LMNA (0.56) HPGDLMNANR3C1ALDH1A1KDM4E
SCHEMBL1017876 0.82 LMNA (0.56) HPGDLMNANR3C1ALDH1A1KDM4E
SCHEMBL1014942 0.82 LMNA (0.56) HPGDLMNANR3C1ALDH1A1KDM4E
SCHEMBL541539 0.81 FLT3 (0.53) HPGDLMNANR3C1ALDH1A1KDM4E
SCHEMBL1014628 0.77 RAB9A (0.53) HPGDLMNANR3C1RAB9ANPC1
SCHEMBL1015585 0.77 RAB9A (0.53) HPGDLMNANR3C1RAB9ANPC1
SCHEMBL1014077 0.77 SMYD3 (0.48) HPGDLMNANR3C1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102066335-A Substituted pyrimidin-5-carboxamides 281 ASTRAZENECA AB 2011-05-18 CN disclosed
EP-2271629-A1 SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 AstraZeneca AB (SE) 2011-01-12 EP disclosed
WO-2009130496-A1 SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 ASTRAZENECA AB (SE) 2009-10-29 WO disclosed
US-20090264401-A1 SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 ASTRAZENECA AB (SE) 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264401-A1 SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 CYP2S1, HSD11B1, HSD3B1 HPGD 54/4885LMNA 4185/4885NR3C1 971/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.